Business Context and Reporting Period
This Form 8-K reports on a special meeting of stockholders held on November 5, 2020, by KBL Merger Corp. IV (the "Company"). The filing details the approval of a business combination with 180 Life Sciences Corp. and related corporate amendments. As of the record date (September 30, 2020), 5,372,161 shares of Common Stock were issued and outstanding.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, or margin data as it is a current report regarding a corporate event rather than a periodic financial statement. However, it discloses specific liquidity figures related to the Trust Account:
- Redemption Amount: Approximately $9,006,492.76 was removed from the Trust Account to pay redeeming shareholders.
- Remaining Trust Balance: Approximately $1,367,364.54 remained in the Trust Account following redemptions.
- Shares Redeemed: 816,461 public shares were redeemed.
Material Changes and Voting Results
Stockholders approved eight proposals with overwhelming support (over 5.1 million votes "FOR" on all proposals). Key material changes include:
- Business Combination: Approval of the merger with 180 Life Sciences Corp., resulting in 180 surviving as a wholly-owned subsidiary.
- Corporate Name Change: The Company will change its name from "KBL Merger Corp. IV" to "180 Life Sciences Corp."
- Capital Structure: Authorization of Common Stock increased from 35,000,000 to 100,000,000 shares; Preferred Stock authorization increased from 1,000,000 to 5,000,000 shares.
- New Share Classes: Creation of Class C and Class K Special Voting Shares to align voting rights with Canadian Exchangeable Shares.
- Stock Issuance: Approval to issue at least 14,911,263 shares of Common Stock to close the combination and up to 2,588,737 shares for future exchanges of Exchangeable Shares.
Outlook, Risks, and Management Commentary
The filing confirms the successful completion of the shareholder vote required to proceed with the business combination. The Company adopted a new 2020 Long Term Incentive Plan. The filing notes that provisions in the Charter relating to the initial business combination (typical of SPACs) were eliminated as they are no longer applicable post-merger. No specific forward-looking financial guidance or risk factors beyond the standard transaction execution were detailed in this specific text.
Investor Verification Checklist
- Verify the final closing date of the business combination with 180 Life Sciences Corp.
- Confirm the post-merger share count and the exact exchange ratio for Canadian Exchangeable Shares.
- Review the terms of the newly adopted 2020 Long Term Incentive Plan for potential dilution.
- Monitor the ticker symbol change from KBLM to the new symbol for 180 Life Sciences Corp.
- Assess the impact of the reduced Trust Account balance ($1.37M) on the company's immediate liquidity post-closing.